Issues
Dynamics of formation of absorbed doses in organs and tissues of laboratory animals from alpha-emitting radionuclides with successive decays
«Radiation and Risk», 2025, vol. 34, No. 2, pp.81-93
DOI: 10.21870/0131-3878-2025-34-2-81-93
Authors
Matveev A.V. – Associate Prof., C. Sc., Phys.-Math. OmSMU. Contacts: 12 Lenina str., Omsk, Russia, 644099. Tel.: +79043251774; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .Tishchenko V.K. – Head of Lab., Dr. Sci., Biol. A. Tsyb MRRC.
1 Omsk State Medical University of the Ministry of Health of the Russian Federation, Omsk
2 A. Tsyb MRRC, Obninsk
Abstract
The main problem in the assessment of the absorbed doses of internal irradiation of drugs marked with alpha-emitting radionuclides is to take into account the radiation loads from all daughter radio-nuclides of sequential decay with alpha and beta transformations. The aim of the work is to develop a methodology for calculating accumulated and total absorbed doses in organs and tissues of laboratory animals from alpha-emitting radionuclides with successive decays within the framework of the pharmacokinetic modeling method. To test the developed technique and calculate the dosimetric characteristics, the actinium-225-labeled drug 225Ac-PSMA (prostate-specific membrane antigen) was selected, intended for targeted peptide-receptor radionuclide therapy of prostate cancer. To identify the necessary parameters, quantitative data on the biodistribution of 225Ac-PSMA in the body of BALB/c nu/nu (nude) mice with subcutaneously implanted malignant prostate tumor (22Rv1) were used. Calculations have shown that the values of accumulated absorbed doses in organs and tissues increase monotonously from the moment the drug is injected into the blood, reaching their maximum values over a period of time equal to five effective half-lives of the drug from the corresponding organ or tissue. The main contribution to the values of total absorbed doses is provided by alpha-emitting parent and daughter radionuclides. The contribution of daughter beta-emitting radionuclides is significantly less. Therefore, they can be ignored in preliminary estimates of absorbed doses. It was re-vealed that 225Ac-PSMA, having a high clearance, is rapidly excreted from the blood mainly by the kidneys. At the same time, the total absorbed dose in the tumor tissue of the prostate gland exceeds several times the total absorbed doses in other organs and tissues, except the liver and kidneys. The results obtained indicate the prospects for further studies of 225Ac-PSMA and the possibility of its clinical application for radionuclide therapy of prostate cancer.
Key words
dosimetry, actinium-225, radiopharmaceutical, radionuclide, compartment modeling, nuclear medicine, absorbed dose, radioactivity, radiobiology.
References
1. Maystrenko D.N., Stanzhevskii A.A., Vazhenina D.A., Odintsova M.V., Popov S.A., Savchenko O.N., Nomokonova V.B., Chipiga L.A., Saprykin K.A., Gromov A.V., Vasiliev S.K. Radioligand therapy with drugs based on radionuclide 225Aс: experience of A.M. Granov Russian scientific center of radiology and sur-gical technologies. Luchevaya diagnostika i terapiya – Diagnostic Radiology and Radiotherapy, 2022, vol. 13, no. 4, pp. 86-94. (In Russian).
2. Nelson B.J.B., Andersson J.D., Wuest F. Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications. Pharmaceutics, 2021, vol. 13, no. 1, pp. 49. DOI: 10.3390/pharmaceu-tics13010049.
3. Muller C., van der Meulen N.P., Benesova M., Schibli R. Therapeutic radiometals beyond 177Lu and 90Y: production and application of promising -particle, -particle, and Auger electron emitters. J. Nucl. Med., 2017, vol. 58, no. 2, pp. 91-96.
4. Belli M.L., Sarnelli A., Mezzenga E., Cesarini F., Caroli P., Di Iorio V., Strigari L., Cremonesi M., Romeo A., Nicolini S., Matteucci F., Severi S., Paganelli G. Targeted alpha therapy in MCRPC (Metastatic Castration-Resistant Prostate Cancer) patients: predictive dosimetry and toxicity modeling of 225Ac-PSMA (Prostate-Spe-cific Membrane Antigen). Front. Oncol., 2020, vol. 10, pp. 531660. DOI: 10.3389/fonc.2020.531660.
5. Kochetova T.Yu., Krylov V.V., Petrosyan K.M., Karyakin O.B., Biryukov V.A., Alekseev B.Ya., Matveev V.B., Ivanov S.A., Kaprin A.D. Radium chloride [223Ra] for patients with prostate cancer and skeletal metastases. Clinical recommendations. Onkourologiya – Cancer Urology, 2020, vol. 16, no. 1, pp. 114-123. (In Russian).
6. Ferrier M.G., Radchenko V. An appendix of radionuclides used in targeted alpha therapy. J. Med. Imaging Radiat. Sci., 2019, vol. 50, no. 4, pp. S58-S65.
7. Radchenko V., Morgenstern A., Jalilian A.R., Ramogida C.F., Cutler C., Duchemin C., Hoehr C., Haddad F., Bruchertseifer F., Gausemel H., Yang H., Osso J.A., Washiyama K., Czerwinski K., Leufgen K., Prus-zyński M., Valzdorf O., Causey P., Schaffer P., Perron R., Maxim S., Wilbur D.S., Stora T., Li Y. Production and supply of -particle-emitting radionuclides for targeted -therapy. J. Nucl. Med., 2021, vol. 62, no. 11, pp. 1495-1503.
8. Orlov M.Yu., Petriev V.M., Skvortsov V.G., Stepanenko V.F. Absorbed doses in the laboratory animal organisms with bone pathology after injection of radiopharmaceuticals 225Ac-KOEDF and 213Bi-KOEDF. Meditsinskaya fizika – Medical Physics, 2012, no. 2, pp. 43-48. (In Russian).
9. Rubira L., Deshayes E., Santoro L., Kotzki P.O., Fersing C. 225Ac-labeled somatostatin analogs in the management of neuroendocrine tumors: from radiochemistry to clinic. Pharmaceutics, 2023, vol. 15, no. 4, pp. 1051-1085.
10. McDevitt M.R., Sgouros G., Finn R.D., Humm J.L., Jurcic J.G., Larson S.M., Scheinberg D.A. Radioim-munotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med., 1998, vol. 25, no. 9, pp. 1341-1351.
11. Morgenstern A., Apostolidis C., Kratochwil C., Sathekge M., Krolicki L., Bruchertseifer F. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr. Radiopharm., 2018, vol. 11, no. 3, pp. 200-208.
12. Petrova A.E., Chipiga L.A., Vodovatov A.V., Stanzhevsky A.A., Maystrenko D.N., Lumpov A.A., Sinyu-khin A.B., Boykov I.V., Rameshvili T.E. Estimation of absorbed doses in patients’ organs from the released radionuclide-label during radionuclide therapy with 225Ac. Radiatsionnaya gygiena – Radiation Hygiene, 2022, vol. 15, no. 1, pp. 120-131. (In Russian).
13. Stuparu A.D., Meyer C.A.L., Evans-Axelsson S.L., Luckerath K., Wei L.H., Kim W., Poddar S., Mona C.E., Dahlbom M., Girgis M.D., Radu C.G., Czernin J., Slavik R. Targeted alpha therapy in a systemic mouse model of prostate cancer − a feasibility study. Theranostics, 2020, vol. 10, no. 6. pp. 2612-2620.
14. Nedrow J.R., Josefsson A., Park S., Back T., Hobbs R.F., Brayton C., Bruchertseifer F., Morgenstern A., Sgouros G. Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 anti-bodies in an immune competent transgenic breast cancer model. EJNMMI Res., 2017, vol. 7, no. 57, pp. 1-16.
15. Kratochwil C., Bruchertseifer F., Rathke H., Bronzel M., Apostolidis C., Weichert W., Haberkorn U., Giesel F.L., Morgenstern A. Targeted -therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J. Nucl. Med., 2017, vol. 58, no. 10, pp. 1624-1631.
16. MCNP – A General Monte Carlo N-Particle Transport Code (Version 4C). LA-13709-M Manual. Ed.: J.F. Briesmeister. Los Alamos, 2000.
17. Sgouros G., He B., Ray N., Ludwig D.L., Frey E.C. Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharma-cokinetic modeling analysis. EJNMMI Phys., 2021, vol. 8, no. 1, pp. 60-75.
18. Matveev A.V., Petriev V.M. Dynamics of formation of absorbed doses in the blood of laboratory animals from alpha-emitting radionuclides with successive decays. Radiatsiya i risk – Radiation and Risk, 2023, vol. 32, no. 3, pp. 134-142. (In Russian).
19. Matveev A.V. Calculation of the dosimetric characteristics of the radiopharmaceutical “188Re-albumin micro-spheres” in the body of mice based on pharmacokinetic modeling. Nauchnyj vestnik OmGMU – Scientific Bulletin of OmSMU, 2024, vol. 4, no. 2, pp. 34-45. (In Russian).
Full-text article (in Russian)